Armas Pharmaceuticals and Micro Labs USA have announced the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The first product, Diphenhydramine Injection 50mg/1mL, is slated to be launched in May. Diphenhydramine has been seen on the FDA Drug Shortage list since September of 2018. Additional product launches are set for the second quarter of 2019. The market size of these products total $100 million annually, according to IMS data.
"Armas Pharmaceuticals is excited to partner with Micro Labs as we look to expand our product line across multiple therapeutic classes," said John Niemi, President and CEO of Armas. "Our first launch with Micro Labs, Diphenhydramine Injection 50mg/1mL, is a medicinal drug used widely in the healthcare space. It is our aim to make this product available at affordable pricing to patients in need of the same. This medication reinforces our ultimate goal to bring high quality, affordable drugs that are needed in the U.S. market."
"Micro and Armas have been working together on various ideas and projects,” Ashok Jain, Director of Micro Labs USA, Inc. said. “We are proud to be associated with Armas and we truly value the rich experience and understanding of the US healthcare sector they bring to the partnership."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!